Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Author:

Robert Caroline1,Ribas Antoni2,Hamid Omid3,Daud Adil4,Wolchok Jedd D.5,Joshua Anthony M.6,Hwu Wen-Jen7,Weber Jeffrey S.8,Gangadhar Tara C.9,Joseph Richard Wayne10,Dronca Roxana Stefania11,Patnaik Amita12,Zarour Hassane M.13,Kefford Richard14,Hersey Peter15,Li Xiaoyun16,Diede Scott J.17,Ebbinghaus Scot17,Hodi F. Stephen18

Affiliation:

1. Gustave Roussy and Paris-Sud University, Villejuif-Paris-Sud, France;

2. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA;

3. The Angeles Clinic and Research Institute, Los Angeles, CA;

4. UC San Francisco, San Francisco, CA;

5. Memorial Sloan Kettering Cancer Center, New York, NY;

6. Princess Margaret Cancer Centre, Toronto, ON, Canada;

7. The University of Texas MD Anderson Cancer Center, Houston, TX;

8. NYU Langone Medical Center, New York, NY;

9. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA;

10. Mayo Clinic, Jacksonville, FL;

11. Mayo Clinic, Rochester, MN;

12. South Texas Accelerated Research Theraputics, San Antonio, TX;

13. University of Pittsburgh, Pittsburgh, PA;

14. Crown Princess Mary Cancer Centre, Sydney, Australia;

15. University of Sydney, Sydney, Australia;

16. Merck & Co., Inc., North Wales, PA;

17. Merck & Co., Inc., Kenilworth, NJ;

18. Dana-Farber Cancer Institute, Boston, MA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3